<DOC>
	<DOCNO>NCT00003717</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness paclitaxel plus estramustine treating patient metastatic prostate cancer respond hormone therapy .</brief_summary>
	<brief_title>Paclitaxel Plus Estramustine Treating Patients With Metastatic Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate ( PSA and/or objective response ) duration response weekly paclitaxel plus estramustine patient metastatic hormone refractory prostate cancer . II . Determine effect quality life regimen patient . OUTLINE : Patients receive paclitaxel IV 1 hour weekly 4 week . Patients receive oral estramustine day , day , day paclitaxel administration week . Courses repeat every 4 week absence unacceptable toxicity disease progression . A quality life questionnaire complete treatment 2 month treatment initiation . PROJECTED ACCRUAL : A total 17 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Estramustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven metastatic ( D1 D2 ) hormone refractory adenocarcinoma prostate one following : Bidimensionally measurable disease Bone metastases rise PSA level PSA disease define rise PSA level prior confirmation D1 D2 disease PSA must great 8 bone PSA disease Hormone failure define progression treatment orchiectomy , LHRH agonist , DES alone , hormonal treatment combination antiandrogen therapy PATIENT CHARACTERISTICS : Age : Not specify Performance status : Zubrod 02 Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT great 2 time ULN Renal : Creatinine great 2.0 mg/dL Other : No active malignancy within past 5 year except nonmelanomatous skin cancer situ cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy No prior estramustine alone combination chemotherapy No prior taxanes No 1 prior chemotherapy regimen Endocrine therapy : Concurrent primary hormonal therapy allow ( LHRH agonist orchiectomy ) At least 4 week since prior antiandrogen therapy least 2 rise PSA level Radiotherapy : At least 4 week since prior radiotherapy At least 8 week since prior strontium89 therapy Surgery : See Disease Characteristics</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2001</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>